Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

mRNA

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Osivax initiates phase 2b trial of influenza A vaccine candidate

The study aims to enrol 2,850 participants across 16 sites in Europe

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

Moderna shares positive phase 3 results for mRNA flu vaccine candidate

More than 600,000 people in the US were hospitalised due to flu-related illness last year

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

Seven strategic steps to enhance patient recruitment & retention in your influenza studies

The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...

Innovative Trials

- PMLiVE

Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

The serious adverse event reported was found to be unrelated to the vaccine

- PMLiVE

Is your influenza clinical trial prepared for the upcoming flu season? Part 3

This blog will discuss some important aspects to consider to maximise patient retention on your flu clinical trials. For more information on patient recruitment considerations, check out our previous blogs...

Innovative Trials

- PMLiVE

Is your influenza clinical trial prepared for the upcoming flu season? Part 2

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and resulting in financial losses for sponsors and research sites (Rangu and Maxwell,...

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links